J Biol Chem, Vol. 274, Issue 37, 26469-26476, September 10, 1999
Calmodulin and Protein Kinase C Increase
Ca2+-stimulated Secretion by Modulating Membrane-attached
Exocytic Machinery*
Yu A.
Chen
§¶,
Vikas
Duvvuri§
**,
Howard
Schulman
, and
Richard H.
Scheller

From the
Howard Hughes Medical Institute, Department
of Molecular and Cellular Physiology, Stanford University School of
Medicine, Stanford, California 94305-5345 and the
Department of
Neurobiology, Stanford University School of Medicine,
Stanford, California 94305-5135
 |
ABSTRACT |
The molecular mechanisms underlying the
Ca2+ regulation of hormone and neurotransmitter
release are largely unknown. Using a reconstituted
[3H]norepinephrine release assay in permeabilized PC12
cells, we found that essential proteins that support the triggering
stage of Ca2+-stimulated exocytosis are enriched in an EGTA
extract of brain membranes. Fractionation of this extract allowed
purification of two factors that stimulate secretion in the absence of
any other cytosolic proteins. These are calmodulin and protein kinase C
(PKC
). Their effects on secretion were confirmed using
commercial and recombinant proteins. Calmodulin enhances secretion in
the absence of ATP, whereas PKC requires ATP to increase secretion, suggesting that phosphorylation is involved in PKC- but not
calmodulin-mediated stimulation. Both proteins modulate release events
that occur in the triggering stage of exocytosis. The half-maximal
increase was elicited by 3 nM PKC and 75 nM
calmodulin. These results suggest that calmodulin and PKC increase
Ca2+-activated exocytosis by directly modulating the
membrane- or cytoskeleton-attached exocytic machinery downstream of
Ca2+ elevation.
 |
INTRODUCTION |
The molecular mechanisms of presynaptic vesicle release have been
extensively examined by a combination of biochemical, genetic, and
electrophysiological techniques. A series of protein-protein interaction cascades have been proposed to lead to vesicle docking and
fusion (1-3). The SNARE protein family, including syntaxin, SNAP-25,
and vesicle-associated membrane protein (VAMP, also called synaptobrevin), plays an essential role in promoting membrane fusion,
and is thought to comprise the basic fusion machinery (4, 5). In
Ca2+-stimulated exocytosis, many additional proteins are
important in the Ca2+ regulation of the basic membrane
trafficking apparatus. Calcium not only triggers rapid fusion of
release-competent vesicles, but is also involved in earlier processes
which replenish the pool of readily releasable vesicles (6).
Furthermore, it appears to be critical in initiating several forms of
synaptic plasticity including post-tetanic potentiation (7). The
molecular mechanisms by which Ca2+ regulates these
processes is not well understood.
PC12 cells have often been utilized to study Ca2+-activated
exocytosis, as they offer a homogeneous cell population that possesses the same basic exocytic machinery as neurons (8). In this study, we
used an established cracked cell assay, in which
[3H]norepinephrine
(NE)1 labeled PC12 cells are
permeabilized by mechanical "cracking" and then reconstituted for
secretion of NE in the presence of test proteins (9).
Transmitter-filled vesicles and intracellular cytoskeletal structures
remain intact in these cells, while cytosolic proteins leak out (10).
These cracked cells readily release NE upon addition of ATP, brain
cytosol, and 1 µM free Ca2+ at an elevated
temperature. We term this a "composite assay," as all essential
components are added into one reaction mixture. Alternatively, cracked
cells can be first primed with cytosol and ATP, washed, then
reconstituted for NE release with cytosol and Ca2+ (11).
This sequential priming-triggering protocol is useful for determining
whether a protein acts early or late in the exocytic pathway and
whether its effect is dependent on Ca2+ or ATP.
This semi-intact cell system serves as a bridge between an in
vitro system comprised of purified components and
electrophysiological systems that monitor release in vivo.
It provides information on protein functions in a cell with an intact
membrane infrastructure while being easily manipulatable.
Ca2+ regulation by membrane depolarization is no longer a
concern, as intracellular Ca2+ concentration can be
controlled by a buffered solution. Indirect readout of neurotransmitter
release using a postsynaptic cell is replaced by direct readout of
[3H]NE released into the buffer. Complications associated
with interpreting overlapping exo- and endocytotic signals are also
eliminated as only one round of exocytosis is measured. Finally,
concentration estimates are likely to be accurate, since added
compounds do not need to diffuse long distances along axons and
dendrites to their sites of action.
Using this assay, several proteins required for NE release have been
purified from rat brain cytosol, including phosphatidylinositol transfer protein (12), phosphatidylinositol-4-phosphate 5-kinase (13),
and calcium-dependent activator protein for secretion (CAPS) (9). The validity of the cracked cell system is confirmed by the
finding that phosphatidylinositol transfer protein and CAPS are
mammalian homologues of yeast SEC14p (12) and nematode UNC31p,
respectively (14), both proteins involved in membrane trafficking (15,
16).
Calmodulin is the most ubiquitous calcium mediator in eukaryotic cells,
yet its involvement in membrane trafficking has not been well
established. Some early studies showed that calmodulin inhibitors
(17-19), anti-calmodulin antibodies (20, 21), or calmodulin binding
inhibitory peptides (22) inhibited Ca2+-activated
exocytosis. However, in other studies, calmodulin-binding peptides and
an anti-calmodulin antibody led to the conclusion that calmodulin is
only involved in endocytosis, not exocytosis (23). More recently, it
was reported that Ca2+/calmodulin signals the completion of
docking and triggers a late step of homotypic vacuole fusion in yeast,
thus suggesting an essential role for Ca2+/calmodulin in
constitutive intracellular membrane fusion (24). If calmodulin indeed
plays an important role in exocytosis, a likely target of calmodulin is
Ca2+/calmodulin-dependent protein kinase II
(CaMKII), a multifunctional kinase that is found on synaptic vesicles
(25) and has been shown to potentiate neurotransmitter release (26,
27).
Another Ca2+ signaling molecule, PKC, has also been
implicated in regulated exocytosis. In various cell systems, it has
been shown that the phorbol esters stimulate secretion (28, 29). It is
usually assumed that phorbol esters effect on exocytosis is through
activation of PKC, but Munc13-1 was recently shown to be a presynaptic
phorbol ester receptor that enhances neurotransmitter release (30, 31),
which complicates the interpretation of some earlier reports. The mode
of action of PKC remains controversial. There is evidence that PKC
increases the intracellular Ca2+ levels by modulating
plasma membrane Ca2+ channels (32, 33), that it increases
the size of the release-competent vesicle pool (34, 35), or that it
increases the Ca2+ sensitivity of the membrane trafficking
apparatus (36). However, no consensus on these issues has been reached.
PKC substrates that have been implicated in exocytosis include SNAP-25
(37), synaptotagmin (28), CAPS (38), and n-sec1 (39). It is
believed that upon phosphorylation, these PKC substrates might interact
differently with their binding partners, which, in turn, leads to the
enhancement of exocytosis. In addition, evidence is accumulating that
PKC and calmodulin interfere with each others actions, as PKC
phosphorylation sites are embedded in the calmodulin-binding
domains of substrates such as neuromodulin and neurogranin (40). It is
therefore possible that PKC could modulate exocytosis via a
calmodulin-dependent pathway by synchronously releasing
calmodulin from storage proteins.
In this study, we fractionated an EGTA extract of brain membranes in
order to identify active components that could reconstitute release in
the cracked cell assay system. We identified calmodulin and PKC as two
active factors. Thus, we demonstrate that calmodulin and PKC play a
role in the Ca2+ regulation of exocytosis, and provide
further insight into the mechanisms of their action.
 |
EXPERIMENTAL PROCEDURES |
Materials
Bisindolylmaleimide I, PKC inhibitor peptide(19-36), human
recombinant PKC
, rat brain PKC, and anti-PKC monoclonal antibody (Ab2) were purchased from Calbiochem (San Diego, CA). Calmodulin from
bovine brain was obtained from Sigma, annexin VI (annexin 67 kDa) from
bovine liver was obtained from Sigma and Biodesign (Kennebunk, ME), and
anti-calmodulin monoclonal antibody was purchased from Upstate
Biotechnology (Lake Placid, NY). Calmodulin-binding peptide (CaMKII aa
291-312) was synthesized at Research Genetics (Huntsville, AL) and
high pressure liquid chromatography purified.
Rat Brain Cytosol Preparation
Frozen rat brains (Harlan, IN) were homogenized in 3 ml/g of
ice-cold homogenization buffer (20 mM Hepes, pH 7.5, 0.25 mM sucrose, 2 mM EGTA, 2 mM EDTA, 2 µg/ml leupeptin, 4 µg/ml aprotinin, 1 mM
dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride)
using a VirTishear homogenizer (Virtis, NY). The homogenate was
centrifuged at 30,000 × g for 20 min, and the
supernatant was centrifuged again at 100,000 × g for
1 h. The resulting supernatant was rapidly frozen in aliquots and
stored at
80 °C.
Membrane EGTA Extract Preparation
Frozen rat or bovine brains (RJO Biologicals, Kansas City, MO)
were homogenized as above, except that the buffer lacks 2 mM EGTA and 2 mM EDTA (1 liter/bovine brain).
The homogenate was centrifuged twice at 3,000 × g for
15 min, and the supernatant centrifuged at 100,000 × g
for 1 h. The 100,000 × g supernatant, if kept,
was rapidly frozen and stored as cytosol. It is referred to in the text
as "cytosol prepared in the absence of EGTA." The pellet of the
100,000 × g spin was washed once by rehomogenization into homogenization buffer without protease inhibitors, using a
Teflon/glass homogenizer, and centrifuged at 100,000 × g for 1 h. The washed membrane pellet was then
rehomogenized into homogenization buffer without protease inhibitors at
about 0.5 ml/g of starting material. EGTA was added to reach 2 mM final concentration, and the extraction was carried out
at 4 °C for a few hours or overnight. The membrane homogenate was
then centrifuged at 100,000 × g for 1 h, and the
supernatant collected as "membrane EGTA extract."
The protein concentration of cytosol and membrane EGTA extract was
estimated using a Bradford protein assay (Bio-Rad), using bovine serum
albumin as a standard. In a typical preparation, the protein
concentration of rat brain cytosol ranges from 7 to 9 mg/ml, and the
membrane EGTA extract 0.3 to 0.6 mg/ml. About 3% of total membrane
proteins can be extracted into the EGTA extract.
Cracked Cell Assay
PC12 cells were maintained and [3H]NE labeled as
described previously (11). Labeled cells were harvested by pipetting
with ice-cold potassium glutamate buffer (50 mM Hepes, pH
7.2, 105 mM potassium glutamate, 20 mM
potassium acetate, 2 mM EGTA) containing 0.1% bovine serum
albumin. All subsequent manipulations were carried out at 0-4 °C
unless otherwise stated. Labeled cells (1-1.5 ml/dish) were
mechanically permeabilized by a single passage through a chilled
stainless steel ball homogenizer. The cracked cells were adjusted to 11 mM EGTA and incubated on ice for 0.5-3 h, followed by
three washes in which the cells were centrifuged at 800 × g for 5 min and resuspended in potassium glutamate buffer
containing 0.1% bovine serum albumin.
Composite Assay--
Each release reaction contains 0.5-1
million cracked cells, 1.5 µM free Ca2+, 2 mM MgATP, and the protein solution to be tested in a total volume of 200 µl of potassium glutamate buffer. Release reactions were initiated by incubation at 30 °C and terminated by returning to
ice after a 15-min incubation. The supernatant of each reaction was
isolated by centrifugation at 2,500 × g for 30 min at
4 °C, and the released [3H]NE was quantified by
scintillation counting (Beckman LS6000IC). Cell pellets were dissolved
in 1% Triton X-100, 0.02% azide and similarly counted. NE release was
calculated as a percentage of total [3H] in the supernatant.
Priming Assay--
A priming reaction contains about 1-2
million cracked cells, 2 mM MgATP, and the protein solution
to be tested in a total volume of 200 µl of potassium glutamate
buffer. Note that Ca2+ is omitted. The reaction was carried
out at 30 °C for 30 min. The primed cells were then spun down,
washed once with fresh potassium glutamate buffer, and distributed into
two triggering reactions, each containing 10 µl of rat brain cytosol
and 1.5 µM free Ca2+ in a total volume of 200 µl of potassium glutamate buffer. The triggering reaction was
performed at 30 °C for 3 min, and the NE release was measured as in
a composite assay.
Triggering Assay--
Cracked cells were primed in potassium
glutamate buffer containing 0.7-1 mg/ml rat brain cytosol and 2 mM MgATP at 30 °C for 30 min. The primed cells were
centrifuged, washed once with potassium glutamate buffer, and
distributed into triggering reactions containing 1.5 µM
free Ca2+ and the protein solution to be tested. To inhibit
any ATP dependent activity in the triggering reaction, where indicated,
an ATP depletion system of 5 units/ml hexokinase (Sigma), 2 mM MgCl2, 10 mM glucose or a
non-hydrolyzable ATP analogue AMP-PNP (5 mM; Sigma) was
added into the triggering reaction. NE release was measured as above.
Free Ca2+ Concentration Determination
The range of [Ca2+]free in the release
reaction (Fig. 2B) was achieved by adding Ca2+
into potassium glutamate buffer to reach final
[Ca2+]total values of 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 1.9, and 2.0 mM. The pH of the reaction was 7.24 when no Ca2+ was added and 7.04 when 2.0 mM
Ca2+ was added, in the absence of protein extracts or
cracked cells. Free Ca2+ concentrations were determined
using video microscopic measurements of fura-2 fluorescence. Imaging
was performed as described previously (41).
[Ca2+]free was calculated from the equation
[Ca2+]free = Kd* × (R
Rmin)/(Rmax
R) (42). The values of Rmin,
Rmax, and Kd* were determined
in the following solutions: 1) Rmin: potassium
glutamate buffer containing 8 × 106 cracked cells/ml,
2 mM MgATP, and 10 mM additional EGTA; 2)
Rmax: potassium glutamate buffer containing
8 × 106 cracked cells/ml, 2 mM MgATP, and
10 mM total Ca2+; 3) Kd*:
potassium glutamate buffer containing 8 × 106 cracked
cells/ml, 2 mM MgATP, 28 mM additional EGTA,
and 18 mM total Ca2+, pH 7.2 ([Ca2+]free = 169 nM, determined
in the absence of cells and MgATP based on fura-2 calibration in
cell-free solutions). These solutions were incubated at 37 °C for 3 min, mixed with fura-2 pentapotassium salt (100 µM;
Molecular Probes, Eugene, OR), and imaged. This procedure allowed us to
take into account changes in fura-2 properties caused by the presence
of permeabilized cells. Duplicate measurements of the above range of
[Ca2+]total gave the following average
[Ca2+]free values: 106, 146, 277, 462, 971, 1468, 1847, and 2484 nM.
Purification of Active Proteins
All procedures were carried out at 4 °C or on ice unless
noted otherwise. Membrane EGTA extract of one or two bovine brain(s) (usually 150 ml/brain) was filtered through cheesecloth and loaded overnight onto a 10- or 20-ml DEAE column packed with DEAE-Sepharose CL-6B beads (Amersham Pharmacia Biotech). The column was washed with
wash buffer (20 mM Hepes, pH 7.5, 0.25 mM
sucrose, 2 mM EGTA, 1 mM dithiothreitol) and
step eluted with 10 column volumes of elution buffer (20 mM
Hepes, pH 7.5, 2 mM EGTA, 400 mM KCl, 1 mM dithiothreitol). 100 µl of every other fraction was
dialyzed overnight into potassium glutamate buffer, and 20 µl tested
in a composite release assay for activity. The active fractions were pooled and dialyzed into zero salt buffer (20 mM Hepes, pH
7.5, 2 mM EGTA) and batch bound to 10 ml of Affi-Gel Blue
beads (Bio-Rad) or DyeMatrex-Green A beads (Amicon) for a few hours.
Blue beads were used in earlier experiments, and Green beads were used
later to specifically deplete CAPS, which was known to bind to Green beads (9). The unbound material was collected, concentrated to about 2 ml using a Centriprep-10 (Amicon), and loaded onto a 120-ml HiPrep
Sephacryl S-200 gel filtration column (Amersham Pharmacia Biotech).
Samples were run on the S-200 column in potassium glutamate buffer at a
flow rate of 7 ml/h. 10-50 µl of every other fraction was tested for
activity in the cracked cell composite assay, and two peaks of activity
were observed (Fig. 3).
The first peak of activity had a predicted molecular mass of 85 kDa.
The corresponding material was adjusted to 10 mM potassium phosphate concentration (pH 7.2) and loaded onto a 1-ml hydroxyapatite column packed with hydroxyapatite Bio-Gel HT (Bio-Rad). The bound material was eluted with a linear potassium phosphate gradient from 10 to 500 mM (pH 7.2) in a 30-ml total volume at a flow rate of about 0.1 ml/min, and 0.4-0.5-ml fractions were collected. 200 µl
of each fraction was dialyzed into potassium glutamate buffer and 20 µl was tested for activity. Meanwhile, the fractions (10 µl each)
were also analyzed by SDS-PAGE and silver staining (Sigma silver stain
kit). The active material was concentrated and resolved on an 8%
polyacrylamide gel. Two Coomassie-stained protein bands that matched
the activity profile (Fig. 6) were excised from the gel, minced into
small pieces, dried, and sequenced by the Stanford PAN facility. The
two polypeptide sequences obtained from the upper band were:
LLNQEEGEYYNVPIXEGD and IRSTLNPRWDESFT. The only bovine protein that
contains both polypeptides is PKC
. The four polypeptide
sequences obtained from the lower band were: YELTGKFERLIVGLMRPPAY,
LIEILASRTNEQIHQLVAA, MLVVLLQGTREEDDVVSEDL, and EMSGDVRDVFVAIVQSVK.
Based on these sequences, the protein band was unambiguously identified
to be bovine annexin VI.
The second S-200 peak has a predicted molecular mass of 25 kDa. The
corresponding material was dialyzed into zero salt buffer (20 mM Tris, pH 7.5, 1 mM EGTA) and injected onto a
Mono-Q HR 5/5 FPLC column (Pharmacia). The FPLC run was performed at
18 °C at 1 ml/min and 1-ml fractions were collected with a linear salt gradient from 0 to 1 M KCl over 71 ml. The fractions
containing proteins (determined by A280) were
dialyzed into potassium glutamate buffer and tested in the cracked cell assay.
Western Blot
Anti-calmodulin antibody and anti-PKC antibody were used at
1:2000 and 1:100 dilution at room temperature for 1 h. ECL
(Amersham) was used for detection.
 |
RESULTS |
A Membrane EGTA Extract Supports NE Release--
Brain cytosol,
prepared as the supernatant of a 100,000 × g
centrifugation of the brain homogenate, effectively stimulates NE
release in the cracked cell assay (Fig.
1) as previously shown (9). We wondered
whether crude extracts other than cytosol could also support NE
release, and we focused our attention on extractable peripheral
membrane proteins. We found that a salt or EGTA extract of brain
membranes, membranes defined as the 100,000 × g pellet
of the crude homogenate, reconstituted secretion in the absence of
cytosol. Whereas the salt extract only slightly enhanced NE release
above background (data not shown), the EGTA extract not only stimulated
NE release to a high level, similar to that supported by cytosol, but
also had a higher specific activity than cytosol (Fig. 1). The ability
of the membrane EGTA extract to support secretion is consistent with
the fact that following cracking, the cells are immediately extracted
with EGTA, and are presumably devoid of most membrane EGTA-extractable
factors. This also suggests that these factors, some of which are
probably Ca2+-dependent membrane-associating
proteins, participate in Ca2+-triggered exocytosis.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
The EGTA extract of brain membranes can
support NE release in the absence of cytosol. Rat brain membrane
EGTA extract (closed triangles) and rat brain cytosol
(closed squares) were prepared as described under
"Experimental Procedures." NE release was measured in a composite
reaction mixture of cracked cells, MgATP, Ca2+, and the
indicated amount of crude extracts.
|
|
The Membrane EGTA Extract Is Enriched in Triggering
Factors--
NE release in cracked cells can be resolved into two
sequential stages, an ATP-dependent priming stage and an
ATP-independent Ca2+-dependent triggering stage
(11), and proteins can be tested for activity in either stage. An
effect in priming indicates an early role for the protein, and an
effect in triggering a late ATP-independent role. Since the protein
composition of the membrane EGTA extract and cytosol are different, we
tested whether they had different activities in the priming stage
versus the triggering stage. We found that the membrane EGTA
extract is enriched in factors that act during triggering stage of NE
release, as the same amount of protein from the membrane EGTA extract
as cytosol gave a higher stimulation in the triggering assay, but not
in the priming assay (Fig.
2A). Regular cytosol is
prepared in a buffer containing 2 mM EGTA, and thus
presumably contains some of the proteins present in the membrane EGTA
extract. Cytosol prepared in the absence of EGTA showed an even lower
specific activity in the triggering assay compared with regular cytosol (Fig. 2A).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 2.
The membrane EGTA extract is enriched in
triggering factors. A, rat brain membrane EGTA extract
(closed triangles), rat brain cytosol (closed
squares), and rat brain cytosol prepared in the absence of EGTA
(open triangles) were tested for their stimulatory effects
either in the priming (left) or triggering
(right) stage of NE release. B, NE release was
measured with varying concentrations of free Ca2+ either in
a composite assay (left) or triggering assay
(right). Addition of 10 µg of rat brain membrane EGTA
extract (closed triangles) or 40 µg of rat brain cytosol
(closed squares) increased NE release as compared with
conditions in which no proteins were added (open
squares).
|
|
Another way to assay whether a protein is involved in priming or
triggering is to analyze the Ca2+ sensitivity of its
effect. If the cells were not primed with ATP, stimulation of NE
release occurred over a relatively wide range of Ca2+
concentrations with the addition of cytosol, (Fig. 2B, left
panel). However, if the cells were primed with ATP before the
addition of cytosol, stimulation was only observed at relatively high
levels of Ca2+ (Fig. 2B, right panel).
Therefore, priming seems to correspond to an increase in release at low
[Ca2+], and triggering corresponds to release at high
[Ca2+]. In contrast to cytosol, membrane EGTA extract
preferentially stimulated release at high [Ca2+] (Fig.
2B), suggesting again that the membrane extract is enriched in triggering factors.
Identification of Calmodulin as an Active Triggering Factor in the
EGTA Extract--
Biochemical fractionation of the bovine brain
membrane EGTA extract was carried out to identify the active components
capable of reconstituting NE release. Activity was assayed in a
composite reaction mixture containing cracked cells, ATP,
Ca2+, and the test protein(s). Note that, except for the
presence of bovine serum albumin in the basal buffer, no other proteins were added to the cell ghosts except for the test protein(s). Initial
tests indicated that at least part of the activity in the membrane EGTA
extract binds to and can be efficiently eluted from an anion exchanger
and hydroxyapatite resin, but does not bind to Amicon color resins. The
starting material was, therefore, sequentially purified using DEAE,
Affi-Gel Blue (or Matrex Green-A), and gel filtration chromotography.
Gel filtration fractionation indicated the presence of two peaks of
activity with predicted molecular masses of 25 and 85 kDa, respectively
(Fig. 3). The low molecular weight active
factor was purified to homogeneity, as judged by a Coomassie-stained
SDS-PAGE gel, after a subsequent Mono-Q fractionation (Fig.
4).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Gel filtration chromatography reveals two
stimulatory factors in the membrane EGTA extract. In order to
purify the active component(s) in the membrane EGTA extract, the crude
extract from one bovine brain was fractionated chromatographically (see
"Experimental Procedures" for details). Fractions from a Sephacryl
S-200 gel filtration column were tested for their activity in
stimulating NE release in the composite assay. The two activity peaks
have predicted molecular masses of 85 and 25 kDa, respectively. The
arrows indicate the retention volume of standard proteins
run on the same column.
|
|

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 4.
The low molecular weight active factor is
calmodulin. A, the membrane EGTA extract from one
bovine brain (Start) was subjected to sequential
fractionation on DEAE, Blue A, and Sephacryl S-200 columns. The pooled
material containing the activity after each chromotographic step was
analyzed by SDS-PAGE and Coomassie staining. The arrowheads
indicate the presence of calmodulin in all the lanes. Calmodulin shows
a mobility shift depending on whether or not Ca2+ is
present during electrophoresis (see panel C). B,
the active material pooled from Sephacryl S-200 was fractionated on a
Mono-Q FPLC column and the fractions (5 µl/fraction) were tested for
activity in a composite assay. The activity peak is shown.
C, the active Mono-Q fractions (5 µl/fraction) were
subjected to SDS-PAGE in the presence of 1 mM EGTA or 0.1 mM Ca2+, and the gels stained with Coomassie
Blue. D, fraction 47 (1 µl) was probed by Western blotting
with a monoclonal anti-calmodulin antibody. No Ca2+ or EGTA
was added during SDS-PAGE.
|
|
We reasoned that the protein might be calmodulin (43) based on the
following observations. 1) It is a relatively small protein (14-18
kDa) that is abundant in the starting extract (Fig. 4A). 2)
It elutes at a very high salt concentration (0.41 M KCl) on the Mono-Q column. 3) It stains negatively in silver stain (data not
shown). 4) Its electrophoretic mobility shifts depending on the
presence or absence of Ca2+ (Fig. 4C). A Western
blot with an anti-calmodulin monoclonal antibody gave a positive signal
(Fig. 4D), confirming our prediction.
Properties of Calmodulin-stimulated Exocytosis--
We used
commercial calmodulin or bacterially expressed recombinant calmodulin
to confirm our purification result; both sources of authentic
calmodulin stimulated NE release as expected. Moreover, we found
that calmodulin stimulates secretion in a triggering assay as well as
in a composite assay (Fig.
5A). The half-maximal increase
was at 75 nM (250 ng/200 µl) final calmodulin
concentration. This is within the broad range of affinities between
calmodulin and its various targets and suggests that the interaction
between calmodulin and its target molecule in exocytosis is in the
physiological range. When the triggering reaction was performed at
different Ca2+ concentrations, calmodulin increased NE
release only at high [Ca2+] (0.4 -2 µM)
similar to the crude EGTA extract (Fig. 5B), suggesting that
calmodulin contributes to the triggering activity of the membrane EGTA
extract. Calmodulin's affinity for Ca2+ has been reported
to be around 1 µM (25), consistent with the Ca2+ requirement for calmodulin-stimulated secretion that
we observed.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 5.
Calmodulin stimulates NE release in the
triggering stage. A, calmodulin (obtained from Sigma)
increased NE release in the triggering assay in a
dose-dependent fashion, in the absence of ATP or any other
cytosolic proteins. In this particular experiment, the maximal release
achieved by addition of rat brain cytosol was 46.5%. B, the
triggering assay was performed with different concentrations of free
Ca2+. Calmodulin (3 µg bacterially expressed recombinant
protein; closed squares) increased NE release with a similar
Ca2+ sensitivity to rat brain membrane EGTA extract (10 µg; closed triangles), as compared with conditions in
which no protein was added (open squares).
|
|
Western analysis with commercial protein as standards indicated that
calmodulin constitutes about 5% of total proteins in the rat brain
membrane EGTA extract and about 2% of total proteins in the rat brain
cytosol (data not shown). In addition, a significant amount of
calmodulin appears to be left in the washed cell ghosts (data not
shown). Based on the activity of saturating levels of pure calmodulin
(releasing 6-10% of total [3H]NE) and crude EGTA
extract (releasing ~45% of total [3H]NE), we estimated
that calmodulin accounts for 13-22% of total activity of the extract.
Consistent with this, a high affinity calmodulin-binding peptide
(CaMKII
(291-312) (44), used at 5 µM) and an
anti-calmodulin antibody (2 µg/200 µl) inhibited about 20% of the
membrane EGTA extract-stimulated release (6.7 µg of extract added;
data not shown).
We showed that calmodulin increased NE release in the triggering stage.
Since regular triggering reactions were performed in the absence of any
added ATP, this suggests that calmodulin enhanced secretion in an
ATP-independent fashion. Furthermore, residual ATP in the cell ghosts
did not play a role, since addition of a hexokinase ATP depletion
system that can deplete millimolar concentrations of ATP within a few
minutes (11) had little effect, as did addition of 5 mM
AMP-PNP, which blocks ATP-dependent enzymatic activity
(Fig. 8A). Therefore, we ruled out the possibility that a
kinase mediates calmodulin's effect.
A series of calmodulin mutants from Paramecium and chicken
were tested for their ability to enhance Ca2+-stimulated
secretion, and none of the mutations abolished the calmodulin effect
(data not shown). These mutations include S101F, M145V, E54K,
G40E/D50N, V35I/D50N within Paramecium calmodulin (45), and
M124Q, M51A/V55A, and M51A/V55A/L32A within chicken calmodulin (46,
47). The Paramecium calmodulin mutants are the result of
naturally occurring mutations that result in aberrations in their
behavior. These mutants can be grouped into two categories according to
their behavior, reflecting their loss of either a Ca2+-dependent Na+ current
(calmodulin N-terminal lobe mutants: E54K, G40E/D50N, and
V35I/D50N) or a Ca2+-dependent K+
current (calmodulin C-terminal lobe mutants: S101F and M145V) (45). The
chicken calmodulin mutants have been shown to differentially activate
myosin light chain kinase (M124Q, M51A/V55A, and M51A/V55A/L32A), CaMKII (M124Q), and CaMKIV (M124Q), and the mutated residues are thought to be important in defining calmodulin's binding specificity (46, 47). Our finding that these mutant calmodulins can stimulate exocytosis suggests that calmodulin-binding domains similar to those of
Paramecium Ca2+/calmodulin-dependent
ion channels, myosin light chain kinase, CaMKII, and CaMKIV, are
unlikely to mediate calmodulin's effect in exocytosis.
Identification of Protein Kinase C as an Active Factor in the EGTA
Extract--
The material containing the high molecular mass (85 kDa)
active factor after gel filtration chromatography was fractionated on a
hydroxyapatite column (Fig. 6). Careful
comparison of the activity and SDS-PAGE profile of the fractions
revealed that among all the visible silver-stained protein bands, only
two have an elution profile similar to the activity
(arrowheads in Fig. 6A). The fractions containing
the activity (Fig. 6B) were pooled, concentrated, resolved
on an 8% polyacrylamide gel and visualized by Coomassie staining (Fig.
6C). The two candidate bands were excised from the gel and
sequenced. The 85-kDa band was identified as PKC
, and the 68-kDa
band as annexin VI.

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 6.
Purification of the high molecular weight
active factor. A, crude membrane EGTA extract of two
bovine brains was subjected to sequential fractionation on DEAE, Matrex
Green, Sephacryl S-200, and HA columns. The active material after each
column was analyzed by SDS-PAGE. The first three lanes were
visualized by Coomassie Blue staining. The fourth lane and
the gel showing HA fractions (10 µl/fraction) were visualized by
silver staining. The two arrowheads indicate the two bands
that were identified in panel C as PKC and annexin VI.
B, the activity of HA fractions 12-25 in a composite
release assay (20 µl/fraction). C, the active HA fractions
(fraction 16-21), were pooled, concentrated, and resolved on an 8%
SDS-PAGE gel. The two candidate Coomassie bands corresponding to the
activity (arrowheads) were excised and sequenced. They were
identified as PKC and annexin VI (see "Experimental
Procedures").
|
|
Since both PKC and annexins have been implicated in exocytosis (28,
48), we tested both for activity. Commercially purified rat brain PKC
and recombinant human PKC
increased NE release, whereas commercially
purified bovine liver annexin VI did not (Fig.
7). Western analysis using commercial PKC
as standards indicated that PKC constitutes about 2% of total proteins
in the EGTA extract and about 0.05% of total proteins in the cytosol
(data not shown), demonstrating a 40-fold enrichment of PKC in the EGTA
extract. Based on the dose-response curve of purified PKC (releasing
15-20% of total [3H]NE when saturated), PKC is
estimated to account for about 33-44% of the total activity of the
starting EGTA extract. A PKC inhibitory peptide (19-36)
(IC50 = 147 nM; used at 500 nM)
inhibited 27% of EGTA extract triggered-release (6.7 µg of extract
added).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 7.
PKC stimulates NE release
dose-dependently. PKC stimulated NE release in a composite assay
in the absence of any other added proteins, whereas annexin VI did not.
Purified rat brain PKC (obtained from Calbiochem), closed
squares; human recombinant PKC (obtained from Calbiochem),
open squares; purified bovine liver annexin VI (obtained
from Biodesign), closed triangles. In this experiment, the
maximal released achieved by adding rat brain cytosol was 64.2%.
|
|
The concentration of PKC needed for half-maximal increase in release
was estimated to be about 3 nM (50 ng/200 µl). The effect of PKC is readily blocked by a competitive inhibitor of the ATP-binding site of PKC, bisindolylmaleimide I, and the PKC inhibitor peptide (19-36), which acts as a pseudo-substrate (data not shown), suggesting that PKC enhances NE release through ATP-dependent
phosphorylation. Consistent with this, PKC increased release in the
composite assay, but not in the triggering assay where ATP is absent
(Fig. 8A). Analysis of PKC
stimulation at different Ca2+ concentrations revealed a
similar profile to calmodulin (Fig. 8B), suggesting that
PKC's substrate protein is involved in the late, high
[Ca2+] requiring step of exocytosis. Therefore, PKC
likely phosphorylates its substrate in the presence of ATP, and the
substrate acts during the ATP-independent Ca2+-triggering
stage to increase NE release. Both PKC- and calmodulin-mediated effects
on NE release utilize the conserved SNARE fusion machinery, as they
could be completely abolished by addition of exogenous syntaxin H3
domains (data not shown). However, the same molecular pathway was not
activated, since their effects were additive (data not shown).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 8.
PKC and calmodulin stimulate the late
triggering reaction in an ATP-dependent and ATP-independent
manner respectively. A, triggering assays were
performed to test the activity of calmodulin (recombinant; black
bars) and PKC (purified rat brain PKC from Calbiochem;
shaded bars) in the absence of ATP. A regular triggering
assay is done in the absence of ATP ( ATP). To deplete residual ATP in
the cells, hexokinase-based ATP depletion was employed
(+Hexo). Alternatively, 5 mM AMP-PNP
(+AMP-PNP) was added in the triggering reaction. Under all
three conditions, calmodulin increased release as compared with the
background (buffer only; white bars), whereas PKC did not.
B, NE release in a composite assay was measured with varying
concentrations of free Ca2+ in the presence of 10 µg of
calmodulin (recombinant; closed triangles), 70 ng of PKC
(purified rat brain PKC from Calbiochem; closed squares), or
buffer only (open squares).
|
|
 |
DISCUSSION |
In this study, we first identified an EGTA extract of brain
membranes as a protein source capable of reconstituting
Ca2+-activated exocytosis in cracked PC12 cells. EGTA only
extracts a small pool of Ca2+-dependent
membrane-associating proteins, and thus it served as an efficient
initial purification step. Further protein chromatography led to the
identification of two active factors in the starting extract,
calmodulin and PKC, which together accounted for about half of the
starting activity. Upon confirmation with commercially obtained
proteins, this result unambiguously demonstrated that calmodulin and
PKC mediate aspects of Ca2+-dependent processes
in exocytosis.
The finding that brain membrane EGTA extract alone is able to replace
cytosol in supporting Ca2+-triggered NE secretion in PC12
cells is somewhat surprising. We suggest that the likely explanation is
2-fold. First, some cytosolic proteins essential for exocytosis have a
membrane-bound pool within permeabilized cells, whose activity might be
sufficient for a normal level of exocytosis. Second, although the
100,000 × g membrane pellet was washed to remove as
many cytosolic proteins as possible, some cytosolic proteins that
associate with membranes in a Ca2+-independent manner are
probably present in the membrane EGTA extract. However, these proteins
likely constitute only a small percentage of the proteins in the
extract, as the characteristics of the activity triggered by the
membrane extract are quite different to that of cytosol (Fig. 2).
Using an unbiased biochemical purification method, we demonstrated that
calmodulin and PKC directly modulate the exocytotic machinery
downstream of Ca2+ entry, and furthermore, that they signal
through membrane-attached molecules to increase exocytosis. These
targets include integral and peripheral membrane proteins, and
cytosolic proteins that have a significant membrane-bound pool. The
modest stimulation by calmodulin and PKC on secretion might suggest a
regulatory role. However, it is also possible that some intermediates
in their signaling pathways are in limiting amounts in the cell ghosts, so that their full effects were not observed. Half-maximal stimulation was obtained at about 3 nM for PKC and at about 75 nM for calmodulin. This is consistent with an enzymatic
role for PKC, and predicts a high-affinity interaction between
calmodulin and its substrate protein.
Ca2+ regulates exocytosis at many different levels. Prior
studies indicated that Ca2+ signaling occurs in the priming
steps as well as in triggering steps (49, 50). Our priming triggering
protocol does not allow Ca2+-dependent priming
events to be assayed, as EGTA is present in the priming reaction.
However, a different approach revealed the existence of both high and
low Ca2+-dependent processes (Fig. 2).
Moreover, this analysis indicated that late triggering events require
high [Ca2+], whereas early priming events require low
[Ca2+]. If, as proposed, there is indeed a pronounced
intracellular spatial and temporal [Ca2+] gradient from
the point of Ca2+ entry during depolarization (51), then,
perhaps triggered events occur closer to the point of Ca2+
entry, while Ca2+-dependent priming events
occur further away from the point of Ca2+ entry. Distinct
Ca2+ sensors at these stages might be appropriately tuned
to different [Ca2+] to handle different tasks. By
analyzing the Ca2+ sensitivity of calmodulin- and
PKC-stimulated release, we addressed the question of whether calmodulin
and PKC plays an early or a late role in vesicle release. We showed
that they both require relatively high [Ca2+] (Fig.
8B), implying that calmodulin and PKC both mediate late triggering events, consistent with some earlier reports (34, 52, 53).
In addition, it is interesting to note that PKC does not alter the
calcium sensitivity of release in cracked cells, in contrast to
observations from the chick ciliary ganglion (36). Therefore, in
contrast to previous electrophysiological studies (28), we are able to
limit the possible modes of PKC action in our system to an increase in
the readily releasable vesicle pool or release sites, or an enhancement
of the probability of release of individual vesicles upon
Ca2+ influx.
The experiments assaying the calcium sensitivity of release (Figs. 2,
5, and 8) demonstrated a drop in release at very high [Ca2+]. This decline in release at high
[Ca2+] has been previously reported (49, 51), and may
represent the true Ca2+ sensitivity of the
Ca2+-sensing mechanism inside cells. However, in our
system, it could also be due to the activation of a variety of
Ca2+-activated proteases, as experiments are usually
performed in the presence of crude extracts, which include
unsequestered proteases.
What might the molecular targets of PKC and calmodulin be? An obvious
calmodulin target molecule is CaMKII, as noted earlier. However, we
showed that calmodulin's effect on exocytosis is ATP-independent, rendering the involvement of a kinase extremely unlikely. Calmodulin has also been shown to associate with synaptic vesicles in a
Ca2+-dependent fashion through synaptotagmin
(54), probably by binding to its C-terminal tail (55), and to promote
Rab3A dissociation from synaptic vesicles (56). However, we found that
there was little calcium-dependent binding of calmodulin to
synaptotagmin either on synaptic vesicles, in a bead binding assay with
recombinant proteins, or in a calmodulin overlay (data not shown). In
addition, using immobilized calmodulin, we did not see significant
Ca2+-dependent pull-down of synaptotagmin or
Rab3A from rat brain extract (data not shown). Recent work has
suggested three other candidate targets for calmodulin, Munc13, Pollux,
and CRAG (57). Pollux has similarity to a portion of a yeast Rab
GTPase-activating protein, while CRAG is related to Rab3 GTPase
exchange proteins. Further work is required to investigate the role of
their interactions with calmodulin in vivo.
The recent report that calmodulin mediates yeast vacuole fusion (24) is
intriguing, as it raises the possibility that calmodulin, a highly
conserved ubiquitous molecule, may mediate many membrane trafficking
events. It is not yet known if the effector molecule of calmodulin is
conserved or variable across species and different trafficking steps.
It is enticing to propose a model for Ca2+ sensing whereby
calmodulin is a high affinity Ca2+ sensor for both
constitutive and regulated membrane fusion. In the case of constitutive
fusion, calmodulin may be the predominant Ca2+ sensor. In
the case of slow, non-local exocytosis of large dense core granules, an
additional requirement for the concerted actions of other molecule(s)
that are better tuned to intermediate rises in [Ca2+]
might exist. At the highly localized sites of fast exocytosis of small
clear vesicles where high [Ca2+] is reached, specialized
low affinity sensor(s) are likely required in addition to calmodulin to
achieve membrane fusion. Therefore, although calmodulin participates in
multiple types of vesicle fusion, the impact of Ca2+
sensing by calmodulin on vesicle release likely varies.
Due to the fact that calmodulin binding to some proteins can be
modulated by PKC phosphorylation, one might suspect that PKC action on
exocytosis proceeds through a calmodulin-dependent pathway. However, we found that the effects of calmodulin and PKC are additive within our system, suggesting that PKC does not act by releasing calmodulin from a substrate that functions as a calmodulin storage protein.
How Ca2+ regulates presynaptic vesicle release has been an
open question for many years. By identifying calmodulin and PKC as modulators of Ca2+-regulated exocytosis and clarifying
their functions, we have extended our knowledge of the release process.
While the basic machinery of membrane fusion is becoming better
understood, the multiple effects of Ca2+ on exocytosis
remain to be elucidated at the molecular level. In addition, the ways
that Ca2+ regulation may be important to the mechanisms of
synaptic plasticity in the central nervous system will be a major focus
in the future.
 |
ACKNOWLEDGEMENTS |
We thank Diana Bautista and Dr. Richard S. Lewis for generous help with [Ca2+]free
determination; Dr. Ching Kung for providing the Paramecium calmodulin mutants, and Dr. Anthony R. Means for providing the chicken
calmodulin mutants. We also thank Dr. Jesse C. Hay for the initial
setup of the cracked cell assay, and Dr. Suzie J. Scales for helpful
comments on the manuscript.
 |
FOOTNOTES |
*
This work was supported in part by Conte Center Grant
MH48108.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§
Contributed equally to the results of this work.
¶
Howard Hughes Medical Institute predoctoral fellow.
**
Supported by Grant NIHGM 08327 from the Jointly Sponsored National
Institutes of Health Predoctoral Training Program in the Neurosciences.

To whom correspondence should be addressed. Tel.: 650-723-9075;
Fax: 650-725-4436; E-mail: scheller@cmgm.stanford.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
NE, norepinephrine;
PKC, protein kinase C;
CaM, calmodulin;
SNAP-25, synaptosome-associated
protein of 25 kDa;
CAPS, calcium-dependent activator
protein for secretion;
SNARE, SNAP (soluble
N-ethylmaleimide-sensitive factor attachment proteins)
receptor;
CaMK, Ca2+/calmodulin-dependent
protein kinase;
PAGE, polyacrylamide gel electrophoresis;
AMP-PNP, adenosine 5'-(
,
-imido)triphosphate;
HA, hydroxyapatite.
 |
REFERENCES |
| 1.
|
Calakos, N.,
and Scheller, R. H.
(1996)
Physiol. Rev.
76,
1-29[Abstract/Free Full Text]
|
| 2.
|
Südhof, T. C.
(1995)
Nature
375,
645-653[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Zucker, R. S.
(1996)
Neuron
17,
1049-1055[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Hanson, P. I.,
Heuser, J. E.,
and Jahn, R.
(1997)
Curr. Opin. Neurobiol.
7,
310-315[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Chen, Y. A.,
Scales, S. J.,
Patel, S. M.,
Doung, Y.-C.,
and Scheller, R. H.
(1999)
Cell
97,
165-174[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Neher, E.,
and Zucker, R. S.
(1993)
Neuron
10,
21-30[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Kamiya, H.,
and Zucker, R. S.
(1994)
Nature
371,
603-606[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Corradi, N.,
Borgonovo, B.,
Clementi, E.,
Bassetti, M.,
Racchetti, G.,
Consalez, G. G.,
Huttner, W. B.,
Meldolesi, J.,
and Rosa, P.
(1996)
J. Biol. Chem.
271,
27116-27124[Abstract/Free Full Text]
|
| 9.
|
Walent, J. H.,
Porter, B. W.,
and Martin, T. F. J.
(1992)
Cell
70,
765-775[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Martin, T. F. J.
(1989)
Methods Enzymol.
168,
225-233[Medline]
[Order article via Infotrieve]
|
| 11.
|
Hay, J. C.,
and Martin, T. F. J.
(1992)
J. Cell Biol.
119,
139-151[Abstract/Free Full Text]
|
| 12.
|
Hay, J. C.,
and Martin, T. F. J.
(1993)
Nature
366,
572-575[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Hay, J. C.,
Fisette, P. L.,
Jenkins, G. H.,
Fukami, K.,
Takenawa, T.,
Anderson, R. A.,
and Martin, T. F. J.
(1995)
Nature
374,
173-177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Ann, K.,
Kowalchyk, J. A.,
Loyet, K. M.,
and Martin, T. F. J.
(1997)
J. Biol. Chem.
272,
19637-19640[Abstract/Free Full Text]
|
| 15.
|
Bankaitis, V. A.,
Aitken, J. R.,
Cleves, A. E.,
and Dowhan, W.
(1990)
Nature
347,
561-562[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Miller, K. G.,
Alfonso, A.,
Nguyen, M.,
Crowell, J. A.,
Johnson, C. D.,
and Rand, J. B.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
12593-12598[Abstract/Free Full Text]
|
| 17.
|
Burgoyne, R. D.,
Geisow, M. J.,
and Barron, J.
(1982)
Proc. R. Soc. Lond. B Biol. Sci.
216,
111-115[Medline]
[Order article via Infotrieve]
|
| 18.
|
Ganguly, A.,
Chiou, S.,
Fineberg, N. S.,
and Davis, J. S.
(1992)
Biochem. Biophys. Res. Commun.
182,
254-261[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Verhage, M.,
Hens, J. J.,
De Grann, P. N.,
Boomsma, F.,
Wiegant, V. M.,
da Silva, F. H.,
Gispen, W. H.,
and Ghijsen, W. E.
(1995)
Eur. J. Pharmacol.
291,
387-398[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Steinhardt, R. A.,
and Alderton, J. M.
(1982)
Nature
295,
114-115
|
| 21.
|
Kenigsberg, R. L.,
and Trifaro, J. M.
(1985)
Neuroscience
14,
335-347[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Birch, K. A.,
Pober, J. S.,
Zavoico, G. B.,
Means, A. R.,
and Ewenstein, B. M.
(1992)
J. Cell Biol.
118,
1501-1510[Abstract/Free Full Text]
|
| 23.
|
Artalejo, C. R.,
Elhamdani, A.,
and Palfrey, H. C.
(1996)
Neuron
16,
195-205[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Peters, C.,
and Mayer, A.
(1998)
Nature
396,
575-580[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Braun, A. P.,
and Schulman, H.
(1995)
Annu. Rev. Physiol.
57,
417-445[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Nichols, R. A.,
Sihra, T. S.,
Czernik, A. J.,
Nairn, A. C.,
and Greengard, P.
(1990)
Nature
343,
647-651[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Chapman, P. F.,
Frenguelli, B. G.,
Smith, A.,
Chen, C.-M.,
and Silva, A. J.
(1995)
Neuron
14,
591-597[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Hilfiker, S.,
and Augustine, G. J.
(1999)
J. Physiol. (Lond.)
515,
1[Abstract/Free Full Text]
|
| 29.
|
Byrne, J. H.,
and Kandel, E. R.
(1996)
J. Neurosci.
16,
425-435[Abstract/Free Full Text]
|
| 30.
|
Betz, A.,
Ashery, U.,
Rickmann, M.,
Augustin, I.,
Neher, E.,
Südhof, T. C.,
Rettig, J.,
and Brose, N.
(1998)
Neuron
21,
123-136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Maruyama, I. N.,
and Brenner, S.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
5729-5733[Abstract/Free Full Text]
|
| 32.
|
Swartz, K. J.
(1993)
Neuron
11,
305-320[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Stea, A.,
Soong, T. W.,
and Snutch, T. P.
(1995)
Neuron
15,
929-940[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Gillis, K. D.,
Mossner, R.,
and Neher, E.
(1996)
Neuron
16,
1209-1220[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Stevens, C. F.,
and Sullivan, J. M.
(1998)
Neuron
21,
885-893[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Yawo, H.
(1999)
J. Physiol.
515.1,
169-180[Abstract/Free Full Text]
|
| 37.
|
Shimazaki, Y.,
Nishiki, T.,
Omori, A.,
Sekiguchi, M.,
Kamata, Y.,
Kozaki, S.,
and Takahashi, M.
(1996)
J. Biol. Chem.
271,
14548-14553[Abstract/Free Full Text]
|
| 38.
|
Nishizaki, T.,
Walent, J. H.,
Kowalchyk, J. A.,
and Martin, T. F.
(1992)
J. Biol. Chem.
267,
23972-23981[Abstract/Free Full Text]
|
| 39.
|
Fujita, Y.,
Sasaki, T.,
Fukui, K.,
Kotani, H.,
Kimura, T.,
Hata, Y.,
Südhof, T. C.,
Scheller, R. H.,
and Takai, Y.
(1996)
J. Biol. Chem.
271,
7265-7268[Abstract/Free Full Text]
|
| 40.
|
Chakravarthy, B.,
Morley, P.,
and Whitfield, J.
(1999)
Trends Neurosci.
22,
12-16[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Dolmetsch, R. E.,
and Lewis, R. S.
(1994)
J. Gen. Physiol.
103,
365-388[Abstract/Free Full Text]
|
| 42.
|
Grynkiewicz, G.,
Poenie, M.,
and Tsien, R. Y.
(1985)
J. Biol. Chem.
260,
3440-3450[Abstract/Free Full Text]
|
| 43.
|
Marshak, D. R.,
Kadonaga, J. T.,
Burgess, R. R.,
Knuth, M. W.,
Brennan, W. A.,
and Lin, S.-H.
(1996)
Strategies for Protein Purification and Characterization: A Laboratory Course Manual
, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
|
| 44.
|
Waxham, M. N.,
Tsai, A.,
and Putkey, J. A.
(1998)
J. Biol. Chem.
273,
17579-17584[Abstract/Free Full Text]
|
| 45.
|
Kink, J. A.,
Maley, M. E.,
Preston, R. R.,
Ling, K. Y.,
Wallen-Friedman, M. A.,
Saimi, Y.,
and Kung, C.
(1990)
Cell
62,
165-174[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Chin, D.,
Sloan, D. J.,
Quiocho, F. A.,
and Means, A. R.
(1997)
J. Biol. Chem.
272,
5510-5513[Abstract/Free Full Text]
|
| 47.
|
Chin, D.,
and Means, A. R.
(1996)
J. Biol. Chem.
271,
30465-30471[Abstract/Free Full Text]
|
| 48.
|
Creutz, C. E.
(1992)
Science
258,
924-931[Abstract/Free Full Text]
|
| 49.
|
Bittner, M. A.,
and Holz, R. W.
(1992)
J. Biol. Chem.
267,
16219-16225[Abstract/Free Full Text]
|
| 50.
|
von Rüden, L.,
and Neher, E.
(1993)
Science
262,
1061-1065[Abstract/Free Full Text]
|
| 51.
|
Augustine, G. J.,
and Neher, E.
(1992)
J. Physiol. (Lond.)
450,
247-271[Abstract/Free Full Text]
|
| 52.
|
Chamberlain, L. H.,
Roth, D.,
Morgan, A.,
and Burgoyne, R. D.
(1995)
J. Cell Biol.
130,
1063-1070[Abstract/Free Full Text]
|
| 53.
|
Bittner, M. A.,
and Holz, R. W.
(1993)
Cell. Mol. Neurobiol.
13,
649-664[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Trifaró, J.-M.,
Fournier, S.,
and Novas, M. L.
(1989)
Neuroscience
29,
1-8[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Perin, M. S.
(1996)
Biochemistry
35,
13808-13816[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Park, J. B.,
Farnsworth, C. C.,
and Glomset, J. A.
(1997)
J. Biol. Chem.
272,
20857-20865[Abstract/Free Full Text]
|
| 57.
|
Xu, X.-Z. S.,
Wes, P. D.,
Chen, H.,
Li, H.-S., Yu, M.,
Morgan, S.,
Liu, Y.,
and Montell, C.
(1998)
J. Biol. Chem.
273,
31297-31307[Abstract/Free Full Text]
|